Neurologic Complications of Sickle Cell Disease

  • Shama FarooqEmail author
  • Fernando D. Testai
Neurology of Systemic Diseases (J. Biller, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Neurology of Systemic Disease


Purpose of Review

Sickle cell anemia is a multiorgan disease with acute and chronic complications. Involvement of the central nervous system (CNS) is associated with increased mortality and morbidity. This review highlights the broad spectrum of neurological complications seen in patients with sickle cell disease.

Recent Findings

Increasing recognition of neurological complications has led to improved diagnostic and treatment options throughout the years. Neurologic complications in sickle cell disease include silent cerebral ischemia, ischemic/hemorrhagic stroke, moyamoya syndrome, posterior reversible encephalopathy syndrome, cerebral fat embolism, and cerebral venous sinus thrombosis. Treatment varies depending on the neurological complication.


Sickle cell disease is the most common hereditary anemia with increasing global disease burden. Early recognition and treatment is imperative.


Sickle cell disease SCD Stroke Silent cerebral ischemia Transcranial Doppler ultrasound 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Piel F, Patil A, Howes R, Nyangiri O, Gething P, Dewi M, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013;381:142–51.CrossRefGoogle Scholar
  2. 2.
    Ware R, de Montalembert M, Tshilolo L, Abboud M. Sickle cell disease. Lancet. 2017;390:311–23.CrossRefGoogle Scholar
  3. 3.
    Kauf T, Coates T, Huazhi L, Mody-Patel N, Hartzema A. The cost of health care for children and adults with sickle cell disease. Am J Hematol. 2009;84:323–7.CrossRefGoogle Scholar
  4. 4.
    Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288–94.PubMedGoogle Scholar
  5. 5.
    Steven A, Raghavan P, Rath T, Gandhi D. Neurologic and head and neck manifestations of sickle cell disease. Hematol Oncol Clin North Am. 2016;30:779–98.CrossRefGoogle Scholar
  6. 6.
    DeBaun M, Gordon M, McKinstry R, Noetzel M, White D, Sarnaik S, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. NEJM. 2014;371:699–710.CrossRefGoogle Scholar
  7. 7.
    • Lawrence C, Webb J. Sickle cell disease and stroke: diagnosis and management. Curr Neurol Neurosci Rep. 2016;16:27 The authors summarize review of acute and chronic management of stroke in sickle cell disease. CrossRefGoogle Scholar
  8. 8.
    Griessenauer C, Lebensburger J, Chua M, Fisher W, Hilliard L, Bemrich-Stolz C, et al. Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease. J Neurosurg Pediatr. 2015;16:64–73.CrossRefGoogle Scholar
  9. 9.
    DeBaun M, Kirkham F. Central nervous system complications and management in sickle cell disease. Blood. 2016;127:829–38.CrossRefGoogle Scholar
  10. 10.
    Parise L, Berliner N. Sickle cell disease: challenges and progress. Blood. 2016;127:789.CrossRefGoogle Scholar
  11. 11.
    Bernaudin F, Verlhac S, Arnaud C, et al. Chronic and acute anemia and extracranial internal carotid stenosis are risk factors for silent cerebral infarcts in sickle cell anemia. Blood. 2016;125:1653–61.CrossRefGoogle Scholar
  12. 12.
    Charneski L, Congdon H. Effects of antiplatelet and anticoagulant medications on the vasoocclusive and thrombotic complications of sickle cell disease: a review of the literature. Am J Health Syst Pharm. 2010;67:895–900.CrossRefGoogle Scholar
  13. 13.
    Nabavizadeh S, Vossough A, Ichord R, Kwiatkowski J, Pukenas B, Smith M, et al. Intracranial aneurysms in sickle cell anemia: clinical and imaging findings. J Neurointerv Surg. 2015;8:434–40.CrossRefGoogle Scholar
  14. 14.
    Solh Z, Taccone M, Marin S, Athale U, Breakey V. Neurological PRESentations in sickle cell patients are not always stroke: a review of posterior reversible encephalopathy syndrome in sickle cell disease. Pediatr Blood Cancer. 2016;63:983–9.CrossRefGoogle Scholar
  15. 15.
    Gaziev J, Marziali S, Paciaroni K, Isgrò A, di Giuliano F, Rossi G, et al. Posterior reversible encephalopathy syndrome after hematopoietic cell transplantation in children with hemoglobinopathies. Biol Blood Marrow Transplant. 2017;23:1531–40.CrossRefGoogle Scholar
  16. 16.
    Alkan O, Kizilkilic E, Kizilkilic O, Yildirim T, Karaca S, Yeral M, et al. Cranial involvement in sickle cell disease. Eur J Radiol. 2010;76:151–6.CrossRefGoogle Scholar
  17. 17.
    Gibbs W, Opatowsky M, Burton E. AIRP best cases in radiologic-pathologic correlation: cerebral fat embolism syndrome in sickle cell β-thalassemia. Radiographics. 2012;32:1301–6.CrossRefGoogle Scholar
  18. 18.
    Oguz M, Aksungur E, Soyupak S, Yildirim A. Vein of Galen and sinus thrombosis with bilateral thalamic infarcts in sickle cell anaemia: CT follow-up and angiographic demonstration. Neuroradiology. 1994;36:155–6.CrossRefGoogle Scholar
  19. 19.
    Ciurea S, Thulborn K, Gowhari M. Dural venous sinus thrombosis in a patient with sickle cell disease: case report and literature review. Am J Hematol. 2006;81:290–3.CrossRefGoogle Scholar
  20. 20.
    Coutinho J. Cerebral venous thrombosis. J Thromb Haemost. 2015;13:S238–44.CrossRefGoogle Scholar
  21. 21.
    Venkataraman A, Adams R. Neurologic complications of sickle cell disease. Handb Clin Neurol. 2014;120:1015–25.CrossRefGoogle Scholar
  22. 22.
    Adams R, Nichols F, Figueroa R, McKie V, Lott T. Transcranial Doppler correlation with cerebral angiography in sickle cell disease. Stroke. 1992;23:1073–7.CrossRefGoogle Scholar
  23. 23.
    Jordan L, Casella J, DeBaun M. Prospects for primary stroke prevention in children with sickle cell anaemia. Br J Haematol. 2012;157:14–25.CrossRefGoogle Scholar
  24. 24.
    •• Mack A, Thompson A. Primary and Secondary stroke prevention in children with sickle cell disease. J Pediatr Health Care. 2017;31:145–54 Authors summarize review of silent cerebral ischemia and strokes their diagnostic criteria along with management. CrossRefGoogle Scholar
  25. 25.
    Arkuszewski M, Melhem E, Krejza J. Neuroimaging in assessment of risk of stroke in children with sickle cell disease. Adv Med Sci. 2010;55:115–29.CrossRefGoogle Scholar
  26. 26.
    Kassim A, Galadanci N, Pruthi S, DeBaun M. How I treat and manage strokes in sickle cell disease. Blood. 2015;125:3401–10.CrossRefGoogle Scholar
  27. 27.
    Chou S, Fasano R. Management of patients with sickle cell disease using transfusion therapy. Hematol Oncol Clin North Am. 2016;30:591–608.CrossRefGoogle Scholar
  28. 28.
    Adams R, Cox M, Ozark S, Kanter J, Schulte P, Xian Y, et al. Coexistent sickle cell disease has no impact on the safety or outcome of lytic therapy in acute ischemic stroke. Stroke. 2017;48:686–91.CrossRefGoogle Scholar
  29. 29.
    Powers W, Rabinstein A, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49:e46–e110.CrossRefGoogle Scholar
  30. 30.
    Adams R, McKie V, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. NEJM. 1998;339:5–11.CrossRefGoogle Scholar
  31. 31.
    Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. NEJM. 2005;353:2769–78.CrossRefGoogle Scholar
  32. 32.
    Abboud M, Yim E, Musallam K, Adams R. Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II. Blood. 2011;118:894–8.CrossRefGoogle Scholar
  33. 33.
    Ware R, Helms R. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood. 2012;119:3925–32.CrossRefGoogle Scholar
  34. 34.
    Ware R, Davis B, Schultz W, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD with transfusions changing to hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2012;387:661–70.CrossRefGoogle Scholar
  35. 35.
    Bernaudin F, Verlhac S, Peffault de Latour R, Dalle JH, Brousse V, Petras E, et al. Association of matched sibling donor hematopoietic stem cell transplantation with transcranial Doppler velocities in children with sickle cell anemia. JAMA. 2019;321:266–76.CrossRefGoogle Scholar
  36. 36.
    Wang W, Ware R, Miller S, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377:1663–72.CrossRefGoogle Scholar
  37. 37.
    Talano J, Cairo M. Hematopoietic stem cell transplantation for sickle cell disease: state of the science. Eur J Haematol. 2014;94:391–9.CrossRefGoogle Scholar
  38. 38.
    Kassim A, Sharma D. Hematopoietic stem cell transplantation for sickle cell disease: the changing landscape. Hematol Oncol Stem Cell Ther. 2017;10:259–66.CrossRefGoogle Scholar
  39. 39.
    Walters M, Hardy K, Edwards S, et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2010;16:263–72.CrossRefGoogle Scholar
  40. 40.
    Bernaudin F, Socie G, Kuentz M, Chevret S, Duval M, Bertrand Y, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007;110:2749–56.CrossRefGoogle Scholar
  41. 41.
    Smith E, McClain C, Heeney M, Scott R. Pial synangiosis in patients with moyamoya syndrome and sickle cell anemia: perioperative management and surgical outcome. Neurosurg Focus. 2009;26:E10.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of NeurologyUniversity of Illinois at Chicago College of MedicineChicagoUSA
  2. 2.Neuropsychiatric InstituteChicagoUSA

Personalised recommendations